The recent Phase 1 clinical trial conducted at City of Hope have shown that a personalized vaccine is safe and effective in treating lymphoplasmacytic lymphoma (LPL). This vaccine is tailored to each patient, helping the immune system to attack cancer cells more effectively. In this small-scale trial (9 patients), promising immune responses were observed with manageable side effects. Researchers are hopeful that this approach will improve outcomes for LPL patients, and further studies are planned to confirm these findings and explore the vaccine's potential in larger populations.

Dr. Larry Kwak, a prominent oncologist and researcher at City of Hope, is leading the development of this personalized cancer vaccine. He also serves as the Scientific Advisor for Renhaim Inc. and his collaboration with this Korean start-up biotech aims to advance innovative cancer therapies using Renhaim's mRNA technology.